J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer, vol.127, pp.2893-917, 2008.

S. Altekruse, C. Kosary, M. Krapcho, N. Neyman, R. Aminou et al., SEER data submission, Cancer Statistics Review, 1975.

J. P. Thakkar, B. J. Mccarthy, and J. L. Villano, Age-specific cancer incidence rates increase through the oldest age groups, Am J Med Sci, vol.348, pp.65-70, 2014.

A. G. Pallis, C. Gridelli, U. Wedding, C. Faivre-finn, G. Veronesi et al., Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology, Ann Oncol, vol.25, pp.1270-83, 2014.

E. Quoix, G. Zalcman, J. P. Oster, V. Westeel, E. Pichon et al., Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, Lancet, vol.378, pp.1079-88, 2011.

, Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group, J Natl Cancer Inst, vol.91, pp.66-72, 1999.

S. Kudoh, K. Takeda, K. Nakagawa, M. Takada, N. Katakami et al., Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904), J Clin Oncol, vol.24, pp.3657-63, 2006.

E. Quoix, J. L. Breton, A. Ducolone, B. Mennecier, A. Depierre et al., First line chemotherapy with gemcitabine in advanced nonsmall cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule, Lung Cancer, vol.47, pp.405-417, 2005.

F. A. Shepherd, R. Pereira, J. Ciuleanu, T. Tan, E. H. Hirsh et al., Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, vol.353, pp.123-155, 2005.

P. Wheatley-price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd, Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21, J Clin Oncol, vol.26, pp.2350-2357, 2008.

J. Y. Han, K. Park, S. W. Kim, D. H. Lee, H. Y. Kim et al., First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, vol.30, pp.1122-1130, 2012.

M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, vol.362, pp.2380-2388, 2010.

C. Zhou, Y. L. Wu, G. Chen, J. Feng, X. Q. Liu et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, vol.12, pp.735-777, 2011.

R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal et al., Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, vol.361, pp.958-67, 2009.

L. V. Sequist, J. C. Yang, N. Yamamoto, K. O'byrne, V. Hirsh et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, vol.31, pp.3327-3361, 2013.

Y. L. Wu, C. Zhou, C. P. Hu, J. Feng, S. Lu et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, vol.15, pp.213-235, 2014.

A. Inoue, K. Kobayashi, K. Usui, M. Maemondo, S. Okinaga et al., Firstline gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, vol.27, pp.1394-400, 2009.

M. Maemondo, Y. Minegishi, A. Inoue, K. Kobayashi, M. Harada et al., First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study, J Thorac Oncol, vol.7, pp.1417-1439, 2012.

K. Tateishi, T. Ichiyama, K. Hirai, T. Agatsuma, S. Koyama et al., Clinical outcomes in elderly patients administered gefitinib as firstline treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study, Med Oncol, vol.30, p.450, 2013.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009.

J. Rowe, S. Patel, M. Mazo-canola, A. Parra, M. Goros et al., An evaluation of elderly patients (>/ = 70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from, Journal of geriatric oncology, vol.5, pp.65-70, 2009.

G. Roviello, L. Zanotti, M. R. Cappelletti, A. Gobbi, M. Dester et al., Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?, Clin Exp Med, 2017.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012.

K. Park, E. H. Tan, K. O'byrne, L. Zhang, M. Boyer et al., Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, vol.17, pp.577-89, 2016.

Y. Urata, N. Katakami, S. Morita, R. Kaji, H. Yoshioka et al., Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L, J Clin Oncol, vol.34, pp.3248-57, 2016.

K. Park, C. J. Yu, S. W. Kim, M. C. Lin, V. Sriuranpong et al., First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study, JAMA oncology, vol.2, pp.305-317, 2016.

J. B. Auliac, C. Fournier, A. Valette, C. Perol, M. Bizieux et al., Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study, Target Oncol, vol.11, pp.167-74, 2016.

R. Corre, L. Greillier, L. Caer, H. Audigier-valette, C. Baize et al., Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study, J Clin Oncol, vol.34, pp.1476-83, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01282337

O. Mir, B. Blanchet, and F. Goldwasser, Drug-induced effects on erlotinib metabolism, N Engl J Med, vol.365, pp.379-80, 2011.